Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer

ConclusionThe addition of bevacizumab to S-1 was tolerable, but not beneficial for patients with previously treated non-squamous NSCLC. We do not recommend further study of this regimen.

Source: Cancer Chemotherapy and Pharmacology - May 21, 2017 Category: Cancer & Oncology Source Type: research